Ventyx Biosciences reported a net loss of $27.0 million for Q2 2025, an improvement from $32.0 million in Q2 2024. The company's R&D and G&A expenses both decreased, contributing to a lower total operating loss. Ventyx maintains a strong cash position of $209.0 million, expected to fund operations into at least H2 2026, and has made significant progress in its Phase 2 clinical trials for VTX3232 and VTX2735.

Ventyx Biosciences reported a net loss of $27.4 million for the first quarter of 2025, an improvement from the $38.6 million net loss in the same period last year. The company ended the quarter with $228.8 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into at least the second half of 2026. The company is advancing multiple Phase 2 studies with topline data expected throughout 2025.

Ventyx Biosciences reported a net loss of $29.4 million for Q4 2024, an improvement from the $46.8 million net loss in Q4 2023. The company's cash, cash equivalents, and marketable securities stood at $252.9 million as of December 31, 2024, which is expected to fund operations into at least H2 2026. R&D expenses decreased significantly to $24.8 million from $42.0 million in the prior year.

Ventyx Biosciences reported a net loss of $35.2 million for the third quarter of 2024, with cash, cash equivalents, and marketable securities totaling $274.8 million as of September 30, 2024. The company believes its current funds are sufficient to support operations into at least the second half of 2026. Phase 2 trials for VTX2735 and VTX3232 are expected to initiate by year-end.

Ventyx Biosciences reported a net loss of $32.0 million for the second quarter of 2024, with cash, cash equivalents, and marketable securities totaling $279.7 million as of June 30, 2024. The company is planning to advance its portfolio of NLRP3 inhibitors into three Phase 2 clinical trials and expects clinical updates from all three trials in 2025.

Ventyx Biosciences reported a net loss of $38.6 million for the first quarter of 2024. As of March 31, 2024, the company's cash, cash equivalents, and marketable securities totaled $302.6 million, expected to fund operations into at least the second half of 2026. Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 are expected to initiate in H2 2024.

Ventyx Biosciences reported its Q4 and full year 2023 financial results, with a net loss of $46.8 million for the quarter and cash, cash equivalents, and marketable securities totaling $252.2 million as of December 31, 2023, expected to fund operations into at least H2 2025.

Ventyx Biosciences reported a net loss of $54.0 million for the third quarter of 2023, with cash, cash equivalents, and marketable securities totaling $300.8 million as of September 30, 2023. The company is focused on advancing its pipeline of oral therapies and expects to provide clinical updates in the first quarter of 2024.

Ventyx Biosciences reported a net loss of $53.3 million for the second quarter ended June 30, 2023. As of June 30, 2023, the company's cash, cash equivalents, and marketable securities totaled $332.3 million, which are expected to fund planned operations into 2025. The company completed enrollment in Phase 2 trials for VTX002 in ulcerative colitis and VTX958 in plaque psoriasis and initiated a Phase 1 trial of VTX3232.

Ventyx Biosciences reported a net loss of $38.9 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $376.9 million as of March 31, 2023, which is expected to fund operations into 2025. Five Phase 2 clinical trials are ongoing.

Ventyx Biosciences reported a net loss of $35.2 million for the fourth quarter of 2022, compared to a net loss of $17.8 million for the fourth quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $356.6 million as of December 31, 2022, which is expected to fund operations into 2025.